Health Care • Industrial Specialties
$22.81 ▲ +0.90
(+4.11%)
MKT CAP: $1.32B • VOL: 1.30M
52W L $17 52W H $32
ENOV // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $2.25B | $2.11B | $1.71B |
| YoY Revenue Growth % | +6.7% | +23.5% | — |
| Gross Profit | $1.35B | $1.18B | — |
| Gross Margin % | 59.8% | 56.0% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$1.12B | -$775.7M | -$65.7M |
| Operating Margin % | -50.0% | -36.8% | -3.8% |
| Net Income (GAAP) | -$1.18B | -$825.5M | -$33.3M |
| EBITDA (Normalized) | -$966.3M | -$631.1M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $217.3M | $113.5M | $135.0M |
| Capital Expenditures (CapEx) | $197.4M | $180.7M | — |
| Free Cash Flow (FCF) | $19.9M | -$67.2M | $135.0M |
| FCF Margin % | 0.9% | -3.2% | 7.9% |
| Return on Invested Capital (ROIC %) | -32.7% | -16.0% | — |
| Cash & Short-Term Equivalents | $36.4M | $48.2M | — |
| Total Debt (Short + Long Term) | $1.26B | $1.31B | — |
| Total Stockholders' Equity | $1.49B | $2.56B | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ENOV.